Pradaxa Side Effects Lawsuits Filed in Federal Court
Los Angeles, CA, March 7, 2012 – National law firm Nadrich & Cohen, LLP has learned that three Pradaxa side effects lawsuits have been filed against Boehringer Ingelheim, the drug’s manufacturer. The cases were filed in federal district courts located in Tennessee, Kentucky and Louisiana and it’s believed they are the first federal lawsuits to be filed in connection with the drug.
Pradaxa (dabigatran) was first approved by the U.S. Food and Drug Administration in 2010 to prevent blood clots and strokes in patients who suffer from a heart rhythm defect known as atrial fibrillation (AF). The drug was designed to be a safer alternative to other blood-thinning medications on the market but has become the subject of scrutiny after research studies have linked Pradaxa to an increased risk of serious bleeding events.
One of the lawsuits filed against Boehringer blames Pradaxa for the wrongful death of a Tennessee woman who began using the drug in January 2011 to treat her atrial fibrillation. According to the woman’s daughter, who filed the suit, Pradaxa caused her to suffer a massive gastrointestinal bleed, which resulted in her death less than three months after she began taking the drug.
In November 2011, Boehringer acknowledged that as many as 260 deaths worldwide had been linked to Pradaxa. The FDA issued an updated safety communication in December 2011, warning patients and health care providers about the potential link between the drug and bleeding risk. The FDA did, however, state that Pradaxa’s benefits outweighed the risk and advised patients to seek medical advice before discontinuing its use.
Just last week, a group of hematologist from New Zealand and Australia announced that a two-month investigative review uncovered 78 cases of bleeding related to Pradaxa, with 44 of these patients experiencing major bleeding events. The researchers, who discussed their findings in a letter to the editor published in the March 1 issue of the New England Journal of Medicine, suggested that at least one patient may have died in connection with prolonged internal bleeding caused by Pradaxa.
Patients who suffered a serious bleeding event or other complications after using Pradaxa are urged to complete a MedWatch form by visiting the Food and Drug Administration’s website. It is also recommended that you contact an experienced Pradaxa injury attorney to discuss your legal rights.
Attorney Jeffrey Nadrich believes that these lawsuits are just the first of many that will likely be filed in connection with injuries or deaths caused by Pradaxa. Nadrich & Cohen LLP offers confidential, no-cost consultations to Pradaxa users who believe they were harmed by the drug. Help is available by calling 1-800-722-0765 or by completing an online case evaluation form at www.personalinjurylawcal.com.
Nadrich & Cohen LLP is a national law firm with offices in Los Angeles, Sacramento, San Diego and other cities throughout California. The firm specializes in handling mass tort actions and representing individuals in cases involving pharmaceutical companies, medical device makers and other product manufacturers. The firm is committed to achieving the best outcome possible in every case and has recovered over $200 million in settlements on behalf of its clients.
In addition to handling Pradaxa side effects claims, Nadrich & Cohen, LLP investigates cases involving Actos, Yaz, Vaginal Mesh, DePuy ASR Hips, Zimmer Hips, Wright Conserve Hips, Stevens-Johnson Syndrome, Reflex Sympathy Dystrophy, Fen Phen and PPH, Depakote and Reglan.
National Client Intake Coordinator
Nadrich & Cohen LLP
12100 Wilshire Blvd.
Los Angeles, CA 90025
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pradaxa Side Effects Lawsuits Filed in Federal Court here
News-ID: 213540 • Views: 2725
More Releases from Nadrich & Cohen LLP
Yaz Lawsuit Settlements Reach $142 Million
Nadrich & Cohen, LLP reports that Bayer is continuing to offer settlements to plaintiffs involved in federal Yaz side effects litigation. Los Angeles, CA, April 27, 2012 – Nadrich & Cohen, LLP reports that German drug-maker Bayer AG has settled approximately 651 Yaz side effects lawsuits totaling $142 million. Earlier this month, it was reported that the drug-maker had reached settlements in approximately 500 cases filed by women who claimed
Yaz, Yasmin to Get New Labels as FDA Warns of Blood Clot Risk
Nadrich & Cohen, LLP reports that Yaz and similar birth control pills are to receive updated warning labels advising patients of the risk for developing serious blood clots. Los Angeles, CA, April 10, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has ordered Bayer to produce new warning labels for several of its oral contraceptives, including Yaz, Yasmin and Beyaz.
FDA Schedules Advisory Panel Meeting to Discuss Metal Hip Safety
Nadrich & Cohen, LLP reports that the FDA has scheduled an advisory panel to discuss the safety of metal hip implants. Los Angeles, CA, March 29, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has a scheduled an advisory panel meeting to discuss the safety of metal hip implants and all-metal hip resurfacing systems. The two-day panel, which is expected
Bayer Agrees to Settlement in 70 Yaz Side Effects Lawsuits
Nadrich & Cohen, LLP reports that Bayer has agreed to settlements with a number of plaintiffs who sued the company over Yaz side effects. Los Angeles, CA, March 5, 2012 – National law firm Nadrich & Cohen, LLP reports that Bayer Healthcare has agreed to settle approximately 70 lawsuits filed on behalf of women who claim they were seriously injured by Yaz birth control pills. The amount of the settlements has
More Releases for Pradaxa
Pradaxa Global Industry Report - History, Present and Future 2018
GET SAMPLE REPORT @ https://www.research2reports.com/sample-report-other-reports/pradaxa-market/71821 The global market size of Pradaxa is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the end of 2023 with a CAGR of XX% from 2018 to 2023. There are 3 key segments covered in this report: geography segment, end use/application segment and competitor segment. For geography segment, regional supply, application-wise and type-wise demand, major
Global Pradaxa Market Top Key Players - Pfizer, Bayer Healthcare, GlaxoSmithKlin …
A new and latest research report proposed by QYResearchReports.us renders a market summary of the Pradaxa Market industry. This widespread analysis comprises of market potentials. This report studies Pradaxa in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. Get Sample Copy of this Report: https://www.qyresearchreports.us/request-sample/global-pradaxa-market-professional-survey-report-2017 This report focuses on
Pradaxa Market- Global Industry Analysis, Growth and Forecast 2017- 2022
In this report, the global Pradaxa market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Request For Sample Of Global Pradaxa Market Research Report @ http://bit.ly/2g7KkJO Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Pradaxa in
United States Pradaxa Market Report 2017
In this report, the United States Pradaxa market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: The West Southwest The Middle Atlantic New England The South The Midwest with sales (volume), revenue (value), market share and growth rate of Pradaxa in these regions, from
Pradaxa Market 2017 - Pfizer, Bayer Healthcare, GlaxoSmithKline, Aspen Holdings
Apex Research, recently published a detailed market research study focused on the "Pradaxa Market" across the global, regional and country level. The report provides 360° analysis of "Pradaxa Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Pradaxa industry, and estimates the future trend of Pradaxa market on the basis of this
Pradaxa Market by Type, Applications, Substrate Type, and by Region - Global For …
The Global Pradaxa Market Research Report 2017 renders deep perception of the key regional market status of the Pradaxa Industry on a Global level that primarily aims the core regions which comprises of continents like Europe, North America, and Asia and the key countries such as United States, Germany, China and Japan. Free Sample PDF Copy of Pradaxa Market research report @ https://www.qyresearchgroups.com/request-sample/488034 The report on “Global Pradaxa Market” is a professional